On May 29, Veeva Systems rose 5.12% in regular trading, trading at $172.7/share, with trading volume of $137 million. A confluence of new client wins, product launches, and pre-earnings positioning fueled the rally.

On the news front, Veeva announced that Teva Pharmaceutical and Germany-based Merck KGaA committed to use its Vault CRM software globally, connecting sales, marketing, and medical teams on a single platform. Separately, CDMO Kindeva adopted Veeva Quality Cloud to standardize manufacturing operations. Additionally, Veeva launched Falcon, an agentic AI platform designed to support drug development projects by integrating clinical, regulatory, and safety applications to reduce costs and maintain compliance for biopharma clients.

Looking ahead, Veeva is scheduled to report quarterly earnings on June 3 after market close. Institutional consensus expects revenue growth of approximately 16.62% year-over-year, with adjusted EPS of $1.55. The company reported $836 million in revenue last quarter with a 74.46% gross margin, and the market anticipates continued subscription revenue momentum, prompting early capital positioning ahead of the report.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)